Harmony Biosciences (HRMY) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
18 May, 2026Opening remarks and agenda
The meeting was called to order at 1:00 P.M. Eastern Time, with the agenda posted on the virtual meeting website and notice provided to all stockholders of record as of March 17, 2026.
Proof of notice, proxy materials, and annual report distribution was confirmed, and a quorum was established, allowing the meeting to proceed.
Company officers, board members, and representatives from the independent accounting firm were present, with rules of conduct posted for orderly proceedings.
Board and executive committee updates
Four Class 3 directors—Gino Germano, Troy Ignelzi, Ron Philip, and Andreas Wicki—were nominated to serve until the 2029 annual meeting.
The board unanimously recommended the election of these nominees.
Shareholder proposals
Three proposals were presented: election of directors, ratification of Deloitte & Touche LLP as independent auditor for 2026, and a non-binding advisory vote on executive compensation.
The board unanimously recommended approval of all proposals.
Latest events from Harmony Biosciences
- Q1 2026 revenue up 17% to $215.4M; full-year guidance reaffirmed at $1.0–$1.04B.HRMY
Q1 20267 May 2026 - WAKIX momentum, pipeline innovation, and strategic BD drive growth and CNS leadership.HRMY
25th Annual Needham Virtual Healthcare Conference13 Apr 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.HRMY
Proxy filing3 Apr 2026 - Shareholders to vote on directors, auditor, and executive pay; strong governance and sustainability highlighted.HRMY
Proxy filing3 Apr 2026 - 2025 revenue up 22% with 2026 WAKIX guidance at $1.0–$1.04B and strong pipeline momentum.HRMY
Q4 202524 Feb 2026 - Four major 2025 catalysts and pipeline innovation drive growth in rare neurological diseases.HRMY
43rd Annual J.P. Morgan Healthcare Conference 20253 Feb 2026 - Robust late-stage CNS pipeline and annual launches drive sustained growth and profitability.HRMY
Investor Day 20243 Feb 2026 - Late-stage CNS pipeline, strong narcolepsy growth, and new formulations drive expansion.HRMY
Goldman Sachs 46th Annual Global Healthcare Conference 20253 Feb 2026 - Q2 2024 revenue up 29% to $172.8M; pipeline expanded, 2024 guidance reaffirmed.HRMY
Q2 20242 Feb 2026